TELIK INC

TELIK INC

Previous company name

Name change date

Company Overview
Telik Inc is a publicly quoted company based in the United States which operates as a biopharmaceutical company engaged in discovering, developing and commercializing novel small molecule drugs to treat cancer and other serious diseases. It was incorporated in the year of 1988 and has its registered corporate headquarters located in Palo Alto, California.
The company’s advanced development candidates are TELCYTA (Canfosfamide HCl), a novel cancer cell-activated chemotherapeutic for ovarian cancer and non-small cell lung cancer; and TELINTRA (Ezatiostat HCl), for cytopenias due to myelodysplastic syndrome or chemotherapy. It develops its product candidates through the use of its proprietary TRAP technology, which enables the rapid and efficient discovery of small molecule drug candidates.
Business Summary
Telik, Inc. (Telik) is a clinical-stage drug development company focused on discovering and developing small molecule drugs to treat cancer. It discovers its product candidates using its drug discovery technology, Target-Related Affinity Profiling (TRAP). TELINTRA, its drug product candidate in clinical development, is a small molecule glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1. Telik is developing TELINTRA for the treatment of blood disorders associated with low blood cell levels, such as neutropenia or anemia. The trial for Myelodysplastic Syndrome (MDS) completed enrollment of 86 patients. During the year ended December 31, 2009, it initiated a Phase II randomized study in Severe Chronic Neutropenia (SCN), to determine the effect of TELINTRA tablets on absolute neutrophil count in patients with this disease. During 2009, Telik initiated a Phase I dose-ranging study of TELINTRA tablets in combination with Lenalidomide in patients with MDS.
Description and history
Telik, Inc. (Telik), incorporated in 1988, is a clinical-stage drug development company focused on discovering and developing small molecule drugs to treat cancer. It discovers its product candidates using its drug discovery technology, Target-Related Affinity Profiling (TRAP). TELINTRA, its drug product candidate in clinical development, is a small molecule glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1. Telik is developing TELINTRA for the treatment of blood disorders associated with low blood cell levels, such as neutropenia or anemia. The trial for Myelodysplastic Syndrome (MDS) completed enrollment of 86 patients. During the year ended December 31, 2009, it initiated a Phase II randomized study in Severe Chronic Neutropenia (SCN), to determine the effect of TELINTRA tablets on absolute neutrophil count in patients with this disease. During 2009, Telik initiated a Phase I dose-ranging study of TELINTRA tablets in combination with Lenalidomide in patients with MDS.

Clinical Product Development Programs

Telik’s two advanced product candidates, TELINTRA and TELCYTA, are being developed to treat cancer. TELINTRA is a small molecule product candidate. In addition, TELINTRA causes the death of human leukemia cells in laboratory tests and this activity may lead to a beneficial effect in the treatment of MDS, a pre-leukemic condition. Telik completed a Phase I-IIa study in patients with MDS using a tablet formulation of TELINTRA. During 2009, it initiated a Phase I dose-ranging study of TELINTRA tablets in combination with Lenalidomide in patients with MDS.

TELCYTA is a small molecule drug product candidate that it is developing for the treatment of cancer. TELCYTA binds to glutathione S-transferase (GST), a protein known to play an important role in the development of resistance to commonly used chemotherapeutic drugs. GST P1-1 is a type of GST that is elevated in many cancers and is often further elevated following treatment with standard chemotherapeutic drugs. When TELCYTA binds to GST P1-1, it releases a fragment with a proven mechanism of killing cancer cells, as well as other reactive agents. In contrast to the usual situation in which GST P1-1 is involved in the destruction of chemotherapeutic drugs, GST P1-1 activates TELCYTA when TELCYTA reaches its cellular target. In this way, TELCYTA kills cancer cells by inducing cell death through a process called apoptosis. TELCYTA has been evaluated in multiple Phase II and Phase III clinical trials, including trials using TELCYTA as monotherapy and in combination regimens in ovarian, non-small cell lung, breast and colorectal cancer.

Preclinical Drug Product Development

TLK60404 is a small molecule compound in preclinical development that inhibits both Aurora kinase and VEGFR kinase. Using its TRAP technology, it has discovered TLK60357, a small molecule inhibitor of cell division. TLK60357 inhibits the formation of microtubules that are necessary for cancer cell growth leading to persistent G2/M cancer cell cycle block and subsequent cell death. TLK60596, a VGFR kinase inhibitor, blocks the formation of new blood vessels in tumors. TLK58747 is a metabolically activated cytotoxic small molecule. TLK58747 induces apoptosis and G2/M, cell cycle arrest in a range of human cancer cell lines including those not expressing GST P1-1.

Research Discovery Programs

The Company’s TRAP drug discovery technology is designed to identify small molecule compounds that act on disease-related protein targets. TRAP technology offers solutions to the two challenges facing drug discovery: the growth in the number of new protein targets generated by the advances in genomics, and the intrinsic limitations of the Ultra High Throughput Screening (UHTS), approach.

Business Line
Operates as a biopharmaceutical company engaged in discovering, developing and commercializing novel small molecule drugs to treat cancer and other serious diseases
Subsidiary

Advisor
ERNST & YOUNG LLP
IPO date
12/2000
US SIC Code
2834
Company Address
3165, Porter Drive

City province or state postal code
94304, PALO ALTO, CA
Phone: +1 650 845 7700
Fax: +1 650 845 7800
Country address: UNITED STATES OF AMERICA
Website url: www.telik.com